---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-21-000138"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:54:13.041721+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q2 revenue $55.1M (+166% YoY); raises 2021 guidance to $200-208M

## Summary
- Total revenue $55.1M, up 166% YoY; net loss $9.0M ($0.13 per share) improved 18%.
- Genomic test volume 20,856, up 215% YoY and 44% sequentially.
- Raises FY2021 revenue guidance to $200-208M from $190-200M.
- Received Medicare coverage for Decipher Bladder; signed managed care contract for Decipher Prostate (~20M members).
- Planned HalioDx acquisition announced; new CFO, CBO, CIO appointed.

## SEC filing metadata
- accession: 0001384101-21-000138
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410121000138/0001384101-21-000138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410121000138/vcyt-20210729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-21-000138
- JSON: https://secwatch.observer/filing/0001384101-21-000138.json
- Plain text: https://secwatch.observer/filing/0001384101-21-000138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.